Jiangsu Yahong Meditech (SHA:688176) or Asieris Pharmaceuticals signed an investigational drug supply agreement with the US Centers for Disease Control and Prevention for its APL-1202 medication for free-living amoeba infections, according to a Monday press release.
The drug is indicated for free-living amoebae causing amoebic meningoencephalitis, which has a 90% mortality rate, the company said.
The US CDC has also submitted an expanded-access investigational new drug application to the US Food and Drug Administration for the use of APL-1202 in laboratory-confirmed or suspected non-keratitis infections caused by free-living amoeba, Asieris said.
Shares fell 2% during Wednesday's late morning trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。